Helen Clare Dearden

University of Leeds — United Kingdom

Medicine · Health Sciences

6h-index525citations18works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(9), CAR-T cell therapy research(6), Health Systems, Economic Evaluations, Quality of Life(4), Immunotherapy and Immune Responses(3), Frailty in Older Adults(3)

Publications18 total

CHEcking Diagnostic Differential Ability of Real Baseline Variables and Frailty Scores in Tolerance of Anti-Cancer Systemic Therapy in OldEr Patients (CHEDDAR-TOASTIE)
Cancers·2025Open Access
1042P Quality of Life (QoL) and updated efficacy outcomes of first-line single-agent cemiplimab in advanced penile carcinoma: The EPIC-B UK multicenter study
Annals of Oncology·2025
A multi-centre review of the use of adjuvant pembrolizumab for renal cell carcinoma.
Journal of Clinical Oncology·2025· 2 cited
EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma.
Journal of Clinical Oncology·2025· 6 cited
EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.
Journal of Clinical Oncology·2025· 6 cited
UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study
BMJ Oncology·2024· 9 citedOpen Access
A United Kingdom prospective, multicentre, observational cohort study investigating tolerance of anti-cancer systemic therapy in the elderly: The TOASTIE study.
Journal of Clinical Oncology·2024· 2 cited
A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC trial).
Journal of Clinical Oncology·2024· 5 cited
The Association of Pre-Existing Autoimmune Disease with Immune Related Adverse Events Secondary to Immune Checkpoint Inhibition Therapy in a Large Multi-Centre UK Population
SSRN Electronic Journal·2024Open Access
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia
Annals of Oncology·2023· 12 citedOpen Access
Observational study investigating Tolerance Of Anticancer Systemic Therapy In the Elderly (TOASTIE): a protocol
BMJ Open·2021· 2 citedOpen Access
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
European Journal of Cancer·2021· 29 cited
Original Research Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
European Journal of Cancer·2021
Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma
Pigment Cell & Melanoma Research·2019· 62 citedOpen Access
Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients
Annals of Oncology·2018· 3 citedOpen Access
Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.
Journal of Clinical Oncology·2018· 2 cited
The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia
Blood·2017· 4 cited
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
Annals of Oncology·2017· 381 citedOpen Access

Frequent Co-authors

Georgina V. Long(8), Alexander M. Menzies(7), Jessica L. Smith(7), Matteo S. Carlino(7), Victoria Atkinson(7), Serigne Lo(5), Shahneen Sandhu(5), Mark Baxter(5), Zeynep Eroglu(4), Douglas B. Johnson(4), Robert M. Mason(4), Andrew Haydon(4), Chloe Khoo(4), Michael Rowe(4), Kieran Zucker(4), Amarnath Challapalli(4), Mehran Afshar(4), Constantine Alifrangis(4), Alastair Thomson(4), Christopher Kent(4)